Genotypic Resistance to Antiretroviral Drugs in Patients Infected with Several HIV Type 1 Genetic Forms in Cuba

2007 ◽  
Vol 23 (3) ◽  
pp. 407-414 ◽  
Author(s):  
Lissette Pérez ◽  
Lucía Pérez Álvarez ◽  
Rocío Carmona ◽  
Carlos Aragonés ◽  
Elena Delgado ◽  
...  
Keyword(s):  
Antiretroviral Drugs ◽  
Genotypic Resistance ◽  
Hiv Type 1

Genotypic Resistance of Antiretroviral Drugs among Drug-Naive HIV Type 1 Patients with the Background of Long-Term Access-Easy Zidovudine Therapy

2003 ◽  
Vol 19 (11) ◽  
pp. 1039-1043 ◽  
Author(s):  
Sang Won Park ◽  
Hong Bin Kim ◽  
Young Ju Choi ◽  
Nam Jung Kim ◽  
Myoung Don Oh ◽  
...  
Keyword(s):  
Antiretroviral Drugs ◽  
Zidovudine Therapy ◽  
Genotypic Resistance ◽  
Drug Naïve ◽  
Hiv Type 1

Characterization of Mutations in HIV Type 1 Isolates from 144 Cambodian Recently Infected Patients and Pregnant Women Naive to Antiretroviral Drugs

2005 ◽  
Vol 21 (11) ◽  
pp. 971-976 ◽  
Author(s):  
Nary Ly ◽  
Patricia Recordon-Pinson ◽  
Viseth Phoung ◽  
Chanthan Srey ◽  
Leang Sim Kruy ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Antiretroviral Drugs ◽  
Hiv Type 1

Inverse Relationship between Viral Load and Genotypic Resistance Mutations in Korean Patients with Primary HIV Type 1 Infections

2006 ◽  
Vol 22 (11) ◽  
pp. 1142-1147 ◽  
Author(s):  
Bum Sik Chin ◽  
Juyeon Choi ◽  
Jeong-Gu Nam ◽  
Mee Kyung Kee ◽  
Soon Deok Suh ◽  
...  
Keyword(s):  
Viral Load ◽  
Inverse Relationship ◽  
Resistance Mutations ◽  
Genotypic Resistance ◽  
Korean Patients ◽  
Hiv Type 1

Comparison of Genotypic Resistance Mutations in Treatment-Naive HIV Type 1-Infected Patients in Korea and China

2010 ◽  
Vol 26 (2) ◽  
pp. 217-221 ◽  
Author(s):  
Bum Sik Chin ◽  
Jun Yong Choi ◽  
Yang Han ◽  
Jiqiu Kuang ◽  
Yanling Li ◽  
...  
Keyword(s):  
Resistance Mutations ◽  
Genotypic Resistance ◽  
Treatment Naïve ◽  
Hiv Type 1

Increasing HIV Type 1 Polymorphic Diversity But No Resistance to Antiretroviral Drugs in Untreated Patients from Central African Republic: A 2005 Study

2006 ◽  
Vol 22 (10) ◽  
pp. 1036-1044 ◽  
Author(s):  
Valerie Marechal ◽  
Valerie Jauvin ◽  
Benjamin Selekon ◽  
Josianne Leal ◽  
Pulcherie Pelembi ◽  
...  
Keyword(s):  
Central African Republic ◽  
Antiretroviral Drugs ◽  
Hiv Type 1

Genotypic Resistance Profile and Clinical Progression of Treatment-Experienced HIV Type 1-Infected Patients with Virological Failure

2008 ◽  
Vol 24 (2) ◽  
pp. 149-154 ◽  
Author(s):  
S. Di Giambenedetto ◽  
M. Colafigli ◽  
C. Pinnetti ◽  
A. Bacarelli ◽  
A. Cingolani ◽  
...  
Keyword(s):  
Virological Failure ◽  
Clinical Progression ◽  
Genotypic Resistance ◽  
Resistance Profile ◽  
Hiv Type 1

Current Peptide HIV Type-1 Fusion Inhibitors

2009 ◽  
Vol 20 (1) ◽  
pp. 1-18 ◽  
Author(s):  
Wei Pang ◽  
Siu-Cheung Tam ◽  
Yong-Tang Zheng
Keyword(s):  
Antiviral Agents ◽  
Antiretroviral Drugs ◽  
Host Cells ◽  
Fixed Dose ◽  
Clinical Use ◽  
The Past ◽  
Fusion Inhibitors ◽  
Hiv Type 1 ◽  
Hiv 1

There are now 26 antiretroviral drugs and 6 fixed-dose combinations, including reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and fusion (or entry) inhibitors, approved by the US Food and Drug Administration for clinical use. Although they are clinically effective when used in combination, none of the existing drugs are considered ideal because of toxic side effects and the ascendance of inducing drug-resistant mutants. Development of new antiviral agents is essential. In the past decades, there has been great progress in understanding the structure of HIV type-1 (HIV-1) gp41 and the mechanism of HIV-1 entry into host cells. This opened up a promising avenue for rationally designed agents to interfere with this process. A number of fusion inhibitors have been developed to block HIV-1 replication. Enfuvirtide (T20) was one of those approved for clinical use. This signalled a new era in AIDS therapeutics. It is a synthetic polypeptide with potent inhibitory activity against HIV-1 infection. However, it is sensitive to proteolytic digestion and resistant virus strains are easily induced with multiple clinical use. One of the directions in designing new fusion inhibitors is to overcome these shortages. In the past years, large numbers of promising fusion inhibitory peptides have emerged. The antiviral activities are more potent or they can act differently from that of T20. Some of these new compounds have great potential to be further developed as therapeutic agents. This article reviewed some recent developments of these peptides and the possible role in anti-HIV-1 therapy.

Sign in / Sign up

Export Citation Format

Share Document